Vitamin B<sub>6</sub> Treatment for Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
J Clin Psychiatry 2007;68(11):1648-1654
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Tardive dyskinesia (TD) is a significant clinical problem. Vitamin B6 is a potent antioxidant and takes part in almost all of the possible mechanisms that are suggested as being associated with appearance of TD. The aims of this study were (1) to reexamine the efficacy and safety of higher doses of vitamin B6 versus placebo in a greater sample of patients for a longer time and (2) to evaluate the carryover effect of vitamin B6.
Method:A 26-week, double-blind, placebo-controlled trial was conducted in a university-based research clinic from August 2002 to January 2005 on 50 inpatients with DSM-IV diagnoses of schizophrenia or schizoaffective disorder and TD. In a double-blind crossover paradigm, all study subjects were randomly assigned to start treatment with either vitamin B6 (daily dose of 1200 mg) or placebo. After 12 weeks of treatment and then a 2-week washout, subjects were crossed over to receive the other treatment for 12 weeks. The primary outcome measure was the change from baseline in Extrapyramidal Symptom Rating Scale (ESRS) scores.
Results: The mean decrease in ESRS clinical global impression scores from baseline to endpoint was 2.4 points in patients treated with vitamin B6 and 0.2 points in patients treated with placebo (p < .0001). The mean decrease in the parkinsonism subscale score was 8.5 points and 1.4 points, respectively (p < .00001), and the mean decrease in the dyskinesia subscale score was 5.2 points and –0.8 points, respectively (p < .0001).
Conclusion: Vitamin B6 appears to be effective in reducing symptoms of TD. The specific mechanisms by which vitamin B6 attenuates symptoms of TD are not clear.